Literature DB >> 2721978

Plasma fluorescein and fluorescein glucuronide in patients with selected eye diseases.

N P Blair1, M A Evans, T S Lesar, M Willett.   

Abstract

Systemically administered fluorescein (F) is rapidly transformed to the fluorescent metabolite fluorescein glucuronide (FG). Little is known about how diseases can influence the synthesis or disposition of FG. We studied F and FG in the plasma ultrafiltrate of 75 people who were normal or had diabetes, retinitis pigmentosa, or idiopathic rhegmatogenous retinal detachment. F and FG were determined by high-performance liquid chromatography. The concentration of FG was comparable to F 1 h after an intravenous injection of F, both in normal subjects and in patients with retinitis pigmentosa, which suggests that FG may not be an important contributor to the vitreous fluorescence at that time. At later times FG substantially exceeded F. The concentration of FG was significantly higher in diabetics than in the other groups 14 h after an oral dose of F. Accordingly, the possible effect of disease on plasma dye concentrations should be considered in studies measuring F by fluorescence hours after systemic F administration, since this could influence the intraocular fluorescence irrespective of any alteration in ocular function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2721978     DOI: 10.1007/BF02169781

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  21 in total

1.  Study of fluorescein glucuronide. II. A comparative ocular kinetic study of fluorescein and fluorescein glucuronide.

Authors:  C Seto; M Araie; M Takase
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

2.  Determination of fluorescein and fluorescein monoglucuronide excreted in urine.

Authors:  S C Chen; H Nakamura; Z Tamura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-09       Impact factor: 1.645

3.  [The effects of fluorescein monoglucuronide on the calculation of the transfer coefficient by diffusion (kdpa) after systemic administration of fluorescein].

Authors:  C Seto; M Araie; M Takase; K Minoda
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1984-12

4.  High-performance liquid chromatographic analysis for fluorescein and fluorescein monoglucuronide in plasma.

Authors:  F Selan; N Blair; M A Evans
Journal:  J Chromatogr       Date:  1985-02-27

5.  Pharmacokinetics of fluorescein in the vitreous.

Authors:  A G Palestine; R F Brubaker
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-10       Impact factor: 4.799

6.  Studies on the metabolites of fluorescein in rabbit and human urine.

Authors:  S C Chen; H Nakamura; Z Tamura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-05       Impact factor: 1.645

7.  Early breakdown of the blood-retinal barrier in diabetes.

Authors:  J Cunha-Vaz; J R Faria de Abreu; A J Campos
Journal:  Br J Ophthalmol       Date:  1975-11       Impact factor: 4.638

8.  Role of fluorescein glucuronide and its metabolism in vitreous fluorophotometry.

Authors:  W E Plehwe; P S Chahal; T J Fallon; J R Cunningham; M J Neal; E M Kohner
Journal:  Exp Eye Res       Date:  1987-02       Impact factor: 3.467

9.  Metabolism of fluorescein after intravenous administration.

Authors:  P S Chahal; M J Neal; E M Kohner
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-05       Impact factor: 4.799

10.  Fluorescein and fluorescein glucuronide pharmacokinetics after intravenous injection.

Authors:  N P Blair; M A Evans; T S Lesar; R C Zeimer
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-07       Impact factor: 4.799

View more
  1 in total

1.  Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer.

Authors:  Liang Li; Ning Gao; Ai Qing Yang; Wen Hao Xu; Yu Ding; Jun Chu; Xiao Na Lin; Jia Qi Liu
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.